AZD0530 study 21 - Phase I study in patients with solid tumours
Study identifier:D8180C00021
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open-label, Dose-escalation Study to Assess the Safety and Tolerability of AZD0530 in Patients with Advanced Solid Malignancies
Medical condition
solid tumor
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD0530
Sex
All
Actual Enrollment
18
Study type
Interventional
Age
20 Years +
Date
Study Start Date: 01 Jun 2008
Primary Completion Date: 01 Jan 2011
Study Completion Date: 01 May 2011
Study design
Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD0530 | Drug: AZD0530 oral, tablet, once daily, dose will be variable |
Contacts
Investigators
Principal Investigator
Mary Stuart
AstraZeneca
